Collegium Pharmaceutical, Inc. (COLL): Price and Financial Metrics

Collegium Pharmaceutical, Inc. (COLL): $15.54

-0.41 (-2.57%)

POWR Rating

Component Grades














  • COLL scores best on the Value dimension, with a Value rank ahead of 96.96% of US stocks.
  • The strongest trend for COLL is in Growth, which has been heading down over the past 179 days.
  • COLL's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

COLL Stock Summary

  • COLL's current price/earnings ratio is 9.42, which is higher than only 22.96% of US stocks with positive earnings.
  • As for revenue growth, note that COLL's revenue has grown -10.69% over the past 12 months; that beats the revenue growth of only 10.49% of US companies in our set.
  • Collegium Pharmaceutical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 12.75%, greater than the shareholder yield of 87.12% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Collegium Pharmaceutical Inc are HCKT, EVR, CREX, WINA, and ATER.
  • COLL's SEC filings can be seen here. And to visit Collegium Pharmaceutical Inc's official web site, go to

COLL Valuation Summary

  • In comparison to the median Healthcare stock, COLL's EV/EBIT ratio is 61.77% lower, now standing at 11.2.
  • Over the past 77 months, COLL's EV/EBIT ratio has gone up 25.6.
  • Over the past 77 months, COLL's price/earnings ratio has gone up 20.3.

Below are key valuation metrics over time for COLL.

Stock Date P/S P/B P/E EV/EBIT
COLL 2021-08-31 2.2 2.9 6.8 11.2
COLL 2021-08-30 2.2 2.9 6.8 11.1
COLL 2021-08-27 2.2 2.9 6.8 11.1
COLL 2021-08-26 2.3 2.9 6.9 11.2
COLL 2021-08-25 2.3 2.9 6.9 11.3
COLL 2021-08-24 2.2 2.9 6.8 11.2

COLL Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 23.05%.
  • The year over year cash and equivalents growth rate now stands at 55.98%.
  • Its year over year price growth rate is now at 7.92%.
COLL's revenue has moved down $14,312,000 over the prior 34 months.

The table below shows COLL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 276.868 103.557 71.517
2021-09-30 325.777 89.936 103.509
2021-06-30 326.11 106.862 106.749
2021-03-31 321.226 121.181 41.964
2020-12-31 310.016 93.942 26.752
2020-09-30 307.948 87.021 17.593

COLL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • COLL has a Quality Grade of B, ranking ahead of 83.9% of graded US stocks.
  • COLL's asset turnover comes in at 0.493 -- ranking 87th of 681 Pharmaceutical Products stocks.
  • IBIO, IRWD, and COCP are the stocks whose asset turnover ratios are most correlated with COLL.

The table below shows COLL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.493 0.608 0.369
2021-03-31 0.498 0.612 0.422
2020-12-31 0.483 0.580 0.341
2020-09-30 0.552 0.522 0.367
2020-06-30 0.638 0.460 0.266
2020-03-31 0.772 0.391 2.336

COLL Price Target

For more insight on analysts targets of COLL, see our COLL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.71 Average Broker Recommendation 1.56 (Moderate Buy)

COLL Stock Price Chart Interactive Chart >

Price chart for COLL

COLL Price/Volume Stats

Current price $15.54 52-week high $25.66
Prev. close $15.95 52-week low $14.04
Day low $15.54 Volume 261,500
Day high $16.29 Avg. volume 373,931
50-day MA $17.59 Dividend yield N/A
200-day MA $18.92 Market Cap 527.16M

Collegium Pharmaceutical, Inc. (COLL) Company Bio

Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.

COLL Latest News Stream

Event/Time News Detail
Loading, please wait...

COLL Latest Social Stream

Loading social stream, please wait...

View Full COLL Social Stream

Latest COLL News From Around the Web

Below are the latest news stories about Collegium Pharmaceutical Inc that investors may wish to consider to help them evaluate COLL as an investment opportunity.

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni On Q4 2021 Results - Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q4 2021 Earnings Conference Call February 24, 2022, 04:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations & Corporate Communications Joe Ciaffoni - President, CEO & Director Colleen Tupper - CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem -...

SA Transcripts on Seeking Alpha | February 25, 2022

Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results

– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million – – Cash Balance of $186.4 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter and full-year 2021 and provided a

Yahoo | February 24, 2022

Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies

Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.

Yahoo | February 24, 2022

Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%

Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.

Yahoo | February 23, 2022

Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues

Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.

Yahoo | February 23, 2022

Read More 'COLL' Stories Here

COLL Price Returns

1-mo -4.84%
3-mo -19.73%
6-mo -13.43%
1-year -34.84%
3-year 31.81%
5-year 76.59%
YTD -16.81%
2021 -6.74%
2020 -2.67%
2019 19.86%
2018 -6.99%
2017 18.56%

Continue Researching COLL

Here are a few links from around the web to help you further your research on Collegium Pharmaceutical Inc's stock as an investment opportunity:

Collegium Pharmaceutical Inc (COLL) Stock Price | Nasdaq
Collegium Pharmaceutical Inc (COLL) Stock Quote, History and News - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5325 seconds.